CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (N1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02900248|
Recruitment Status : Terminated (Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.)
First Posted : September 14, 2016
Last Update Posted : April 2, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Neoplasms Lung Neoplasms Colon Neoplasms Breast Neoplasms Pancreatic Neoplasms Prostate Neoplasms Kidney Neoplasms Liver Neoplasms Rectal Neoplasms Hematologic Neoplasms Multiple Myeloma Myelodysplastic Syndromes Ovarian Neoplasms Bladder Neoplasms Testicular Neoplasms Endometrial Neoplasms Brain Neoplasms Biliary Tract Neoplasms Head and Neck Neoplasms Uterine Cervical Neoplasms Skin Neoplasms Melanoma Gastric Neoplasms Anal Neoplasms Sarcoma||Other: Provider determined|
Every malignancy or myelodysplasia is different on a molecular (genetic) level even in patients with the same diagnosis. These differences often give prognostic information, determine what types of treatments are available for a patient, as well as determine outcomes. In this registry, the method of identifying the genetic difference of the disease (using Next Generation Sequencing or NGS) is standardized, the treatments received by a patient, and the outcome of these treatments are entered into a database where all identifying information is removed.
Payers (insurance companies) or others will generally pay for the testing, laboratories will report the genetic information, physicians and eventually patients will report treatments and outcomes. This information will then be reviewed frequently and analyzed to find better methods to improve the testing or treatments of disease.
It is expected that dozens of other trials or registries will eventually be available for participants.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||23 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A CureOne Observational Registry (N1)|
|Actual Study Start Date :||October 2, 2017|
|Actual Primary Completion Date :||March 29, 2019|
|Actual Study Completion Date :||March 29, 2019|
Provider Determined Treatment
Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.
Other: Provider determined
Provider will treat patient as he/she feels best
- Best Overall Response [ Time Frame: 5 years ]Best overall response by line of therapy and biomarker
- Time to Treatment Progression [ Time Frame: 5 years ]Physician-determined Time to Treatment Progression by line of therapy and method of determining progression (worsening of disease, new lesions, clinical decline, and/or other).
- Overall Survival [ Time Frame: 5 years ]Overall survival by biomarker
- Establish stable estimates of biomarker prevalence in patients with advanced malignancies in a large population. [ Time Frame: 5 years ]Establish stable estimates of biomarker prevalence in patients with advanced malignancies in a large population.
- To determine rate of enrollment into existing and future therapeutic clinical trials. [ Time Frame: 5 years ]To determine rate of enrollment into existing and future therapeutic clinical trials.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Patient is ≥ 18 years old.
- Patient is able to understand and agrees to comply with the requirements of the study and provides written informed consent indicating voluntary consent to participate in the registry. If the patient is unable to provide consent, but is able to comply with other study requirements, informed consent must be obtained by a durable power of attorney or healthcare proxy.
Patient is diagnosed with any of the following malignancies or disorders AND with the corresponding American Joint Commission on Cancer (AJCC) 7th Edition Staging OR listed clinical scenario (i.e. a patient initially diagnosed with early stage lung cancer would not be a candidate, but if they later developed metastatic disease, they would be eligible and could be enrolled in this registry):
Solid Malignancies Tumor Type (Initial Stage: Clinical Scenario) Lung and Bronchus (Stage IIIB or IV: Metastatic or Extensive) Colorectal (Stage IVB: Metastatic) Pancreas (Stage IV: Metastatic) Breast (Stage IV: Metastatic) Prostate (Stage IV: Castrate resistant) Hepatobiliary (Non-resectable: Metastatic) Tumor of Unknown Primary (Non-resectable: Initial Diagnosis) Bladder (Stage IV: Metastatic) Esophageal (Stage IV: Metastatic) Brain and CNS (All: Initial Diagnosis) Ovarian Cancer (Stage IV or Non-resectable: Recurrent) Kidney or Renal Pelvis (Stage IV: Metastatic) Stomach (Stage IV: Metastatic) Endometrial (Stage IV: Metastatic) Melanoma (Stage IV: Metastatic) Oral Cavity and Pharynx (Stage IVC: Metastatic) Less common Solid Malignancies* (Stage IV: Metastatic)
*Defined as <1% annual death rate in the SEER database. This also includes histologies of common tumors that have been shown to have a more aggressive phenotype and require a different treatment approach than their more common counterparts.
- Hematologic Malignancies Tumor Type (Initial Stage: Clinical Scenario) Non-Hodgkins Lymphoma (N/A: Progressed or relapsed after initial treatment) Multiple Myeloma (Non-smoldering disease: Requiring Treatment) Acute Myelogenous Leukemia (N/A: Initial Diagnosis or Relapse) Chronic Lymphocytic Leukemia (N/A: Progressed or relapsed after initial therapy) Acute Lymphoblastic Leukemia (N/A: Initial Diagnosis or Relapse) Hodgkins Lymphoma (N/A: Progressed or relapsed after initial therapy) Chronic Myelogenous Leukemia (N/A: Progressed or relapsed after initial therapy) Less common Hematologic Malignancies (N/A: Requiring Treatment)
- Myelodysplasia with cytopenias at time of requiring treatment
- Unless otherwise specified, all participants will have NGS testing of an appropriate somatic tissue specimen (biopsy tissue or cell-free DNA) at a CureOne approved lab using the testing outlined in the protocol. The specimen used for testing must have been obtained within 6 months (180 days) preceding consent or on a specimen(s) obtained within 3 months (90 days) following consent to participate in this observational registry. Any non-registry biomarker testing must also be reported. Patient will be treated by physician-determined care plan.
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at initial screening.
- Patient is willing and able to be treated by physician-determined care plan.
- Patient may participate in other clinical studies or registries while participating in this observational registry.
- Patient agrees with regular follow up (see Assessment Schedule below).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02900248
|United States, Idaho|
|Teton Cancer Institute|
|Idaho Falls, Idaho, United States, 83404|
|Principal Investigator:||Razelle Kurzrock, M.D.||Moores Cancer Center, University of California at San Diego|
|Study Chair:||John Pfeifer, M.D., Ph.D.||Washington University School of Medicine|
|Study Director:||Dane J. Dickson, M.D.||CureOne/Knight Cancer Center, Oregon Health and Science University|
|Other Study ID Numbers:||
|First Posted:||September 14, 2016 Key Record Dates|
|Last Update Posted:||April 2, 2019|
|Last Verified:||August 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||De-identified genomic and general outcome information will be available for further research through curated independent research projects|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
High-Throughput Nucleotide Sequencing
Head and Neck Neoplasms
Uterine Cervical Neoplasms
Urinary Bladder Neoplasms
Biliary Tract Neoplasms
Neoplasms by Histologic Type
Neoplasms, Plasma Cell